$4.44 Million in Sales Expected for Sage Therapeutics, Inc. (NASDAQ:SAGE) This Quarter

Equities research analysts forecast that Sage Therapeutics, Inc. (NASDAQ:SAGEGet Rating) will post sales of $4.44 million for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have issued estimates for Sage Therapeutics’ earnings. The lowest sales estimate is $1.48 million and the highest is $32.12 million. Sage Therapeutics reported sales of $1.58 million during the same quarter last year, which indicates a positive year-over-year growth rate of 181%. The company is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Sage Therapeutics will report full-year sales of $28.47 million for the current year, with estimates ranging from $6.00 million to $129.61 million. For the next fiscal year, analysts forecast that the company will report sales of $126.27 million, with estimates ranging from $8.32 million to $289.61 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Sage Therapeutics.

Sage Therapeutics (NASDAQ:SAGEGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($2.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.16) by $0.04. The firm had revenue of $1.65 million for the quarter, compared to analyst estimates of $1.77 million. Sage Therapeutics had a negative return on equity of 24.43% and a negative net margin of 7,258.91%. The business’s quarterly revenue was down 99.9% compared to the same quarter last year. During the same period last year, the company earned ($2.47) EPS.

A number of equities research analysts have recently weighed in on SAGE shares. StockNews.com began coverage on Sage Therapeutics in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. The Goldman Sachs Group dropped their price target on Sage Therapeutics to $96.00 and set a “buy” rating on the stock in a research report on Thursday, February 17th. Morgan Stanley dropped their price target on Sage Therapeutics from $61.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 10th. Needham & Company LLC lifted their price objective on Sage Therapeutics from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, January 6th. Finally, Mizuho lowered their price objective on Sage Therapeutics from $44.00 to $41.00 and set a “neutral” rating for the company in a research note on Thursday, March 3rd. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $63.16.

Shares of SAGE stock opened at $35.25 on Monday. The firm has a market cap of $2.08 billion, a P/E ratio of -4.52 and a beta of 1.65. Sage Therapeutics has a fifty-two week low of $30.48 and a fifty-two week high of $80.87. The business’s 50 day moving average price is $35.58 and its 200-day moving average price is $39.52.

Institutional investors have recently bought and sold shares of the stock. Princeton Global Asset Management LLC bought a new stake in Sage Therapeutics during the third quarter valued at about $44,000. Metropolitan Life Insurance Co NY bought a new position in shares of Sage Therapeutics in the fourth quarter worth about $44,000. Van ECK Associates Corp boosted its stake in shares of Sage Therapeutics by 59.3% in the third quarter. Van ECK Associates Corp now owns 1,203 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 448 shares during the period. US Bancorp DE boosted its stake in shares of Sage Therapeutics by 19.7% in the third quarter. US Bancorp DE now owns 1,885 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 310 shares during the period. Finally, Macquarie Group Ltd. boosted its stake in shares of Sage Therapeutics by 100.4% in the third quarter. Macquarie Group Ltd. now owns 3,363 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 1,685 shares during the period. Institutional investors own 82.64% of the company’s stock.

Sage Therapeutics Company Profile (Get Rating)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.

Featured Stories

Get a free copy of the Zacks research report on Sage Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.